Point-of-Care Ultrasound Detection of Acute Myocardial Dysfunction Following Bupropion Overdose: A Case Report - Cureus

Background: Timely reperfusion remains the cornerstone of management in ST-segment elevation myocardial infarction (STEMI). However, a substantial proportion of patients continue to present beyond the recommended reperfusion window, particularly in low- and middle-income countries. The outcomes associated with delayed coronary revascularization in these late presenters remain incompletely defined. This retrospective observational study aimed to compare one-year mortality and left ventricular ejection fraction (LVEF) changes according to treatment strategy among STEMI patients presenting more than 12 hours after symptom onset. Methods: We conducted a retrospective observational cohort study including consecutive patients admitted with STEMI more than 12 hours after symptom onset between January 2020 and December 2025 at Mohammed VI University Hospital, Marrakech, Morocco. Patients were stratified according to treatment strategy into delayed percutaneous coronary intervention (PCI), conservative medical management, and coronary artery bypass grafting (CABG). The primary endpoint was one-year all-cause mortality, and the secondary outcome was change in LVEF. Mortality comparisons were

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

News|Articles|October 15, 2026 ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates. Automated breast ultrasound (ABUS) detected breast cancer at a rate similar to handheld ultrasound (HHUS) in women with dense breasts while producing fewer abnormal interpretations, fewer false-positive initial assessments, and fewer recommendations for short-interval follow-up, according to an observational study published in the October 2026 issue of the Journal of the American College of Radiology. The analysis, drawn from more than 25,000 supplemental screening examinations in US community practice, was not designed to establish sensitivity or specificity, and ABUS may not be appropriate for every patient with dense breast tissue. According to the investigators and an accompanying news release, this is the first study to directly compare the screening performance of the 2 modalities in clinical practice in the United States. Why does supplemental ultrasound screening matter for patients with dense breasts?

A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate that ABUS is a viable alternative to HHUS and can expand supplemental ultrasound screening capacity at radiology clinics, according to investigators. There is increasing demand for ultrasound screening in addition to mammography following the enactment of state laws and federal rules requiring radiology clinics to inform women with dense breasts about the limitations of mammography. Because dense tissue and lesions both appear white on a mammogram, abnormalities can more easily go undetected.